ribosomal protein L15 pseudogene 1Genealiases: RPL15_9_1687 · dJ726N1.3
Q-omics provides the consensus-scored RPL15P1 profile across patient tissues and cancer cell-line models. RPL15P1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL15P1 is differentially expressed in 6, with the highest sampling consensus in UCEC. Additionally, RPL15P1 RNA expression shows 5,594 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, UCEC, and STAD as cancer lineages where RPL15P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL15P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL15P1 survival associations across molecular data types. RPL15P1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL15P1 RNA expression–survival associations across cancer types. High RPL15P1 expression shows unfavorable associations in COAD, but favorable associations in KIRP, PAAD, ESCA, LUSC and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL15P1 RNA expression.
This table summarizes RPL15P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL15P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL15P1 shows lower tumor expression in KIRC and higher tumor expression in UCEC, PRAD, COAD, LUSC and HNSC. The UCEC box plot shows higher RPL15P1 RNA expression in tumor versus normal tissue (log2 FC = +0.324, t-test p = .011).
This table shows molecular features associated with RPL15P1 in patient tissues and cancer cell lines. In patient samples, RPL15P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
